Executive summary The Stanford–Lancet Commission on the North American Opioid Crisis
was formed in response to soaring opioid-related morbidity and mortality in the USA and …

Even though evidence-based treatment for opioid use disorders (OUD) is effective, almost
four in five Americans with OUD do not receive any form of treatment. The gap in access to …

On October 30 and 31, 2018, the Committee on Medication-Assisted Treatment (MAT) for
Opioid Use Disorder (OUD) held a 1.5-day workshop in Washington, DC. To support the …

The prevalence of opioid use and misuse has provoked a staggering number of deaths over
the past two and a half decades. Much attention has focused on individual risks according to …

Medication treatment (MT) is one of the few evidence-based strategies proposed to combat
the current opioid epidemic. We examined national trends and correlates of offering MT in …

The tables below support the Kaiser Family Foundation February 2017 brief titled,“The
Effects of Medicaid Expansion under the ACA: Updated Findings from a Literature …

In response to the concurrent opioid overdose and COVID-19 epidemics, the United States
(US) Drug Enforcement Administration (DEA) and other federal agencies have taken steps …

At the ten year mark since the passage of the Affordable Care Act (ACA), a substantial body
of research has investigated effects of the Medicaid expansion on coverage; access to care …

Importance Expanding Medicaid eligibility could affect prescriptions of buprenorphine with
naloxone, an established treatment for opioid use disorder, and opioid pain relievers …

Importance The Patient Protection and Affordable Care Act (ACA) permits states to expand
Medicaid coverage for most low-income adults to 138% of the federal poverty level and …